Evidence-Based Medicine Journal ClubEdited by Eric B Milbrandt. University of Pittsburgh Department of Essential Care MedicineExpanded Cilostazol AbstractCitationRidker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby selleckchem Nintedanib P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent Vascular Events in Guys and Girls with Elevated C-Reactive Protein. NEJM 2008, 359: 2195-2207 .BackgroundIncreased levels on the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular occasions. Since statins decrease levels of high-sensitivity C-reactive protein likewise as cholesterol, we hypothesized that folks with elevated high-sensitivity C-reactive protein ranges but with out hyperlipidemia might benefit from statin therapy.
MethodsObjectiveTo investigate whether or not treatment method with rosuvastatin, 20 mg day-to-day, as when compared with placebo, would lower selleck screening library the fee of to start with significant cardiovascular occasions.DesignRandomized, double-blind, placebo-controlled, multicenter trial.Setting1315 web-sites in 26 nations.Subjects17,802 apparently healthy guys and females with low-density lipoprotein (LDL) cholesterol amounts of less than 130 mg per deciliter (three.four mmol per liter) and high-sensitivity C-reactive protein amounts of two.0 mg per liter or greater.InterventionSubjects had been randomly assigned to rosuvastatin, 20 mg everyday, or placebo.OutcomesThe major outcome was the occurrence of a initial big cardiovascular event, defined as myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. Secondary endpoints integrated the elements in the main finish point thought of individually at the same time as death from any trigger.ResultsThe trial was stopped following a median follow-up of one.9 years (optimum, five.0).